Frontlight ResearchEarly access
Active, not recruitingPhase 4
Complete remission study
Key facts
- Who runs it
- Rigshospitalet
- Where
- Denmark6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 66 people, planned
- Started
- 3 Apr 2025
- Expected to end
- 2 Dec 2027
- Type of study
- Interventional
- Record updated
- 13 November 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective is to find out if the patients that have been treated with a monoklonal antibody for nasal polyps, after years of treatmen, can stop the treatment with out recurrence of symptoms.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- English title: Complete remission study Subtitle: Discontinuation of Mepolizumab or Dupilumab after at least 12 months without symptoms in patients with severe Chronic rhinosinusitis with polyps – a National Danish RCT study.
- Record updated
- 13 November 2025